Vir Biotechnology, Inc.
(NASDAQ : VIR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 1.46%243.821.3%$795.90m
IMMUImmunomedics, Inc. 0.07%85.3611.0%$697.18m
MRNAModerna, Inc. 6.60%69.470.0%$666.49m
NVAXNovavax, Inc. 10.86%113.5696.5%$629.01m
ILMNIllumina, Inc. 4.74%299.893.5%$582.79m
GILDGilead Sciences, Inc. 0.00%62.251.0%$574.11m
REGNRegeneron Pharmaceuticals, Inc. 2.98%574.062.7%$443.39m
VRTXVertex Pharmaceuticals, Inc. 1.92%268.181.9%$340.86m
BIIBBiogen, Inc. 1.20%273.281.6%$334.97m
ALXNAlexion Pharmaceuticals, Inc. 2.15%114.432.0%$285.22m
EXASEXACT Sciences Corp. 3.60%97.7020.7%$257.29m
SRNESorrento Therapeutics, Inc. 4.84%9.641.5%$240.99m
VXRTVaxart, Inc. 7.40%7.400.0%$213.88m
SGENSeattle Genetics, Inc. 3.08%184.956.0%$212.14m
MNTAMomenta Pharmaceuticals, Inc. 0.02%52.403.0%$193.58m

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.